Scientists launch bold attack on rare, deadly 'Mixed' leukemia
NCT ID NCT06991920
Summary
This study is testing a new combination treatment for adults with a rare and aggressive type of leukemia called Acute Leukemia of Ambiguous Lineage (ALAL). It will combine an immunotherapy drug (blinatumomab), a targeted drug (venetoclax), and standard chemotherapy to see if this approach is safe and more effective than current options. The goal is to better control the disease and improve survival for the 50 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.